Regulatory evaluation of biosimilars throughout their product life-cycle

The World Health Assembly in 2014 adopted a resolution that recognized the importance of increasing access to biotherapeutic products, of improving their affordability and of ensuring their quality, safety and efficacy. Biosimilars are biotherapeutic products similar to already licensed reference pr...

Full description

Saved in:
Bibliographic Details
Published in:Bulletin of the World Health Organization 2018-04, Vol.96 (4), p.281-285
Main Authors: Kang, Hye-Na, Knezevic, Ivana
Format: Article
Language:English
Subjects:
Access
Affordability
Biological products
Biological Products - therapeutic use
Biosimilar Pharmaceuticals - therapeutic use
Chronic illnesses
Collaboration
Constraints
Drug and Narcotic Control
Drugs
Effectiveness
Efficacy
Health care
Health Services Accessibility
Humans
Interest groups
Licensure
Life cycles
Manufacturing
Markets
Medical treatment
Oversight
Patients
Pharmacovigilance
Policy & Practice
Process controls
Product safety
Public health
Quality
Quality assessment
Quality standards
Regulatory agencies
Safety
Standardization
Trust
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c376t-5e908946daacdac41f1390f62472ad38503bdc7ab67cd0be24ff3934419c83503
cites cdi_FETCH-LOGICAL-c376t-5e908946daacdac41f1390f62472ad38503bdc7ab67cd0be24ff3934419c83503
container_end_page 285
container_issue 4
container_start_page 281
container_title Bulletin of the World Health Organization
container_volume 96
creator Kang, Hye-Na
Knezevic, Ivana
description The World Health Assembly in 2014 adopted a resolution that recognized the importance of increasing access to biotherapeutic products, of improving their affordability and of ensuring their quality, safety and efficacy. Biosimilars are biotherapeutic products similar to already licensed reference products and are usually developed after patents on the original products have expired. Their introduction into the market is likely to reduce the costs of medicines substantially, thereby improving the availability of treatment for patients. However, there are barriers to market access for biosimilars. This article discusses the factors that give rise to these barriers and explains the importance of regulatory oversight throughout the product life-cycle of biosimilars. The paper also describes the role regulators can play in increasing confidence in biosimilars use by: (i) establishing regulatory oversight of biosimilars throughout their life-cycle, from development to post-licensing oversight, and ensuring that only high-quality, safe and efficacious biosimilars are available on the market; (ii) ensuring regulatory authorities have adequate capacity to assess and monitor the quality, safety and efficacy of biosimilars throughout their life-cycle; and (iii) monitoring the use of biosimilars in public health systems in collaboration with other stakeholders.
doi_str_mv 10.2471/BLT.17.206284
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5872015</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2051199865</sourcerecordid><originalsourceid>FETCH-LOGICAL-c376t-5e908946daacdac41f1390f62472ad38503bdc7ab67cd0be24ff3934419c83503</originalsourceid><addsrcrecordid>eNpdkUtLAzEUhYMoWh9LtzLgxs3UvCaTbAQVX1AQpK5DJpNpI-mkJpNC_70p1aLezb1wPg73cAA4R3CMaY2u7ybTMarHGDLM6R4YoYrREjJI98EIQopLwTg7AscxfsA8gsJDcIQFExXndASe38wsOTX4sC7MSrmkBuv7wndFY320C-tUiMUwDz7N5j4N-TQ2FMvg26SHwtnOlHqtnTkFB51y0Zx97xPw_vgwvX8uJ69PL_e3k1KTmg1lZQTkgrJWKd0qTVGHiIAdy1mwagmvIGlaXauG1bqFjcG064gglCKhOcnqCbjZ-i5TszCtNv0QlJPLYBcqrKVXVv5VejuXM7-SFa8xRFU2uPo2CP4zmTjIhY3aOKd641OUGBJEEaNwg17-Qz98Cn2Ol6kKISE421DlltLBxxhMt3sGQbnpSOaOJKrltqPMX_xOsKN_SiFfpeeNoQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2051199865</pqid></control><display><type>article</type><title>Regulatory evaluation of biosimilars throughout their product life-cycle</title><source>International Bibliography of the Social Sciences (IBSS)</source><source>ABI/INFORM Global (ProQuest)</source><source>Social Science Premium Collection</source><source>Politics Collection</source><source>PAIS Index</source><source>PubMed Central</source><creator>Kang, Hye-Na ; Knezevic, Ivana</creator><creatorcontrib>Kang, Hye-Na ; Knezevic, Ivana</creatorcontrib><description>The World Health Assembly in 2014 adopted a resolution that recognized the importance of increasing access to biotherapeutic products, of improving their affordability and of ensuring their quality, safety and efficacy. Biosimilars are biotherapeutic products similar to already licensed reference products and are usually developed after patents on the original products have expired. Their introduction into the market is likely to reduce the costs of medicines substantially, thereby improving the availability of treatment for patients. However, there are barriers to market access for biosimilars. This article discusses the factors that give rise to these barriers and explains the importance of regulatory oversight throughout the product life-cycle of biosimilars. The paper also describes the role regulators can play in increasing confidence in biosimilars use by: (i) establishing regulatory oversight of biosimilars throughout their life-cycle, from development to post-licensing oversight, and ensuring that only high-quality, safe and efficacious biosimilars are available on the market; (ii) ensuring regulatory authorities have adequate capacity to assess and monitor the quality, safety and efficacy of biosimilars throughout their life-cycle; and (iii) monitoring the use of biosimilars in public health systems in collaboration with other stakeholders.</description><identifier>ISSN: 0042-9686</identifier><identifier>EISSN: 1564-0604</identifier><identifier>DOI: 10.2471/BLT.17.206284</identifier><identifier>PMID: 29695884</identifier><language>eng</language><publisher>Switzerland: World Health Organization</publisher><subject>Access ; Affordability ; Biological products ; Biological Products - therapeutic use ; Biosimilar Pharmaceuticals - therapeutic use ; Chronic illnesses ; Collaboration ; Constraints ; Drug and Narcotic Control ; Drugs ; Effectiveness ; Efficacy ; Health care ; Health Services Accessibility ; Humans ; Interest groups ; Licensure ; Life cycles ; Manufacturing ; Markets ; Medical treatment ; Oversight ; Patients ; Pharmacovigilance ; Policy &amp; Practice ; Process controls ; Product safety ; Public health ; Quality ; Quality assessment ; Quality standards ; Regulatory agencies ; Safety ; Standardization ; Trust</subject><ispartof>Bulletin of the World Health Organization, 2018-04, Vol.96 (4), p.281-285</ispartof><rights>Copyright World Health Organization Apr 2018</rights><rights>(c) 2018 The authors; licensee World Health Organization. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c376t-5e908946daacdac41f1390f62472ad38503bdc7ab67cd0be24ff3934419c83503</citedby><cites>FETCH-LOGICAL-c376t-5e908946daacdac41f1390f62472ad38503bdc7ab67cd0be24ff3934419c83503</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2051199865/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2051199865?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,11686,12845,21385,21392,27864,27922,27923,33221,33609,33610,33983,33984,36058,36059,43731,43946,44361,53789,53791,73991,74238,74665</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29695884$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kang, Hye-Na</creatorcontrib><creatorcontrib>Knezevic, Ivana</creatorcontrib><title>Regulatory evaluation of biosimilars throughout their product life-cycle</title><title>Bulletin of the World Health Organization</title><addtitle>Bull World Health Organ</addtitle><description>The World Health Assembly in 2014 adopted a resolution that recognized the importance of increasing access to biotherapeutic products, of improving their affordability and of ensuring their quality, safety and efficacy. Biosimilars are biotherapeutic products similar to already licensed reference products and are usually developed after patents on the original products have expired. Their introduction into the market is likely to reduce the costs of medicines substantially, thereby improving the availability of treatment for patients. However, there are barriers to market access for biosimilars. This article discusses the factors that give rise to these barriers and explains the importance of regulatory oversight throughout the product life-cycle of biosimilars. The paper also describes the role regulators can play in increasing confidence in biosimilars use by: (i) establishing regulatory oversight of biosimilars throughout their life-cycle, from development to post-licensing oversight, and ensuring that only high-quality, safe and efficacious biosimilars are available on the market; (ii) ensuring regulatory authorities have adequate capacity to assess and monitor the quality, safety and efficacy of biosimilars throughout their life-cycle; and (iii) monitoring the use of biosimilars in public health systems in collaboration with other stakeholders.</description><subject>Access</subject><subject>Affordability</subject><subject>Biological products</subject><subject>Biological Products - therapeutic use</subject><subject>Biosimilar Pharmaceuticals - therapeutic use</subject><subject>Chronic illnesses</subject><subject>Collaboration</subject><subject>Constraints</subject><subject>Drug and Narcotic Control</subject><subject>Drugs</subject><subject>Effectiveness</subject><subject>Efficacy</subject><subject>Health care</subject><subject>Health Services Accessibility</subject><subject>Humans</subject><subject>Interest groups</subject><subject>Licensure</subject><subject>Life cycles</subject><subject>Manufacturing</subject><subject>Markets</subject><subject>Medical treatment</subject><subject>Oversight</subject><subject>Patients</subject><subject>Pharmacovigilance</subject><subject>Policy &amp; Practice</subject><subject>Process controls</subject><subject>Product safety</subject><subject>Public health</subject><subject>Quality</subject><subject>Quality assessment</subject><subject>Quality standards</subject><subject>Regulatory agencies</subject><subject>Safety</subject><subject>Standardization</subject><subject>Trust</subject><issn>0042-9686</issn><issn>1564-0604</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>7TQ</sourceid><sourceid>8BJ</sourceid><sourceid>ALSLI</sourceid><sourceid>DPSOV</sourceid><sourceid>M0C</sourceid><sourceid>M2L</sourceid><sourceid>M2R</sourceid><recordid>eNpdkUtLAzEUhYMoWh9LtzLgxs3UvCaTbAQVX1AQpK5DJpNpI-mkJpNC_70p1aLezb1wPg73cAA4R3CMaY2u7ybTMarHGDLM6R4YoYrREjJI98EIQopLwTg7AscxfsA8gsJDcIQFExXndASe38wsOTX4sC7MSrmkBuv7wndFY320C-tUiMUwDz7N5j4N-TQ2FMvg26SHwtnOlHqtnTkFB51y0Zx97xPw_vgwvX8uJ69PL_e3k1KTmg1lZQTkgrJWKd0qTVGHiIAdy1mwagmvIGlaXauG1bqFjcG064gglCKhOcnqCbjZ-i5TszCtNv0QlJPLYBcqrKVXVv5VejuXM7-SFa8xRFU2uPo2CP4zmTjIhY3aOKd641OUGBJEEaNwg17-Qz98Cn2Ol6kKISE421DlltLBxxhMt3sGQbnpSOaOJKrltqPMX_xOsKN_SiFfpeeNoQ</recordid><startdate>20180401</startdate><enddate>20180401</enddate><creator>Kang, Hye-Na</creator><creator>Knezevic, Ivana</creator><general>World Health Organization</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7RV</scope><scope>7T2</scope><scope>7TQ</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88C</scope><scope>88E</scope><scope>88J</scope><scope>8AF</scope><scope>8AO</scope><scope>8BJ</scope><scope>8C1</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>8G5</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DHY</scope><scope>DON</scope><scope>DPSOV</scope><scope>DWQXO</scope><scope>FQK</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>JBE</scope><scope>K60</scope><scope>K6~</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KC-</scope><scope>L.-</scope><scope>L6V</scope><scope>M0C</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2L</scope><scope>M2O</scope><scope>M2R</scope><scope>M7S</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PATMY</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180401</creationdate><title>Regulatory evaluation of biosimilars throughout their product life-cycle</title><author>Kang, Hye-Na ; Knezevic, Ivana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c376t-5e908946daacdac41f1390f62472ad38503bdc7ab67cd0be24ff3934419c83503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Access</topic><topic>Affordability</topic><topic>Biological products</topic><topic>Biological Products - therapeutic use</topic><topic>Biosimilar Pharmaceuticals - therapeutic use</topic><topic>Chronic illnesses</topic><topic>Collaboration</topic><topic>Constraints</topic><topic>Drug and Narcotic Control</topic><topic>Drugs</topic><topic>Effectiveness</topic><topic>Efficacy</topic><topic>Health care</topic><topic>Health Services Accessibility</topic><topic>Humans</topic><topic>Interest groups</topic><topic>Licensure</topic><topic>Life cycles</topic><topic>Manufacturing</topic><topic>Markets</topic><topic>Medical treatment</topic><topic>Oversight</topic><topic>Patients</topic><topic>Pharmacovigilance</topic><topic>Policy &amp; Practice</topic><topic>Process controls</topic><topic>Product safety</topic><topic>Public health</topic><topic>Quality</topic><topic>Quality assessment</topic><topic>Quality standards</topic><topic>Regulatory agencies</topic><topic>Safety</topic><topic>Standardization</topic><topic>Trust</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kang, Hye-Na</creatorcontrib><creatorcontrib>Knezevic, Ivana</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection【Remote access available】</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Source (ProQuest)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>PAIS Index</collection><collection>ABI商业信息数据库</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>ProQuest_Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>International Bibliography of the Social Sciences (IBSS)</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>PAIS International</collection><collection>PAIS International (Ovid)</collection><collection>Politics Collection</collection><collection>ProQuest Central Korea</collection><collection>International Bibliography of the Social Sciences</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>International Bibliography of the Social Sciences</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>Consumer Health Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Politics Collection</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ProQuest Engineering Collection</collection><collection>ABI/INFORM Global (ProQuest)</collection><collection>ProQuest Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Political Science Database</collection><collection>ProQuest research library</collection><collection>Social Science Database (ProQuest)</collection><collection>Engineering Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Environmental Science Database</collection><collection>One Business (ProQuest)</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Bulletin of the World Health Organization</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kang, Hye-Na</au><au>Knezevic, Ivana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Regulatory evaluation of biosimilars throughout their product life-cycle</atitle><jtitle>Bulletin of the World Health Organization</jtitle><addtitle>Bull World Health Organ</addtitle><date>2018-04-01</date><risdate>2018</risdate><volume>96</volume><issue>4</issue><spage>281</spage><epage>285</epage><pages>281-285</pages><issn>0042-9686</issn><eissn>1564-0604</eissn><abstract>The World Health Assembly in 2014 adopted a resolution that recognized the importance of increasing access to biotherapeutic products, of improving their affordability and of ensuring their quality, safety and efficacy. Biosimilars are biotherapeutic products similar to already licensed reference products and are usually developed after patents on the original products have expired. Their introduction into the market is likely to reduce the costs of medicines substantially, thereby improving the availability of treatment for patients. However, there are barriers to market access for biosimilars. This article discusses the factors that give rise to these barriers and explains the importance of regulatory oversight throughout the product life-cycle of biosimilars. The paper also describes the role regulators can play in increasing confidence in biosimilars use by: (i) establishing regulatory oversight of biosimilars throughout their life-cycle, from development to post-licensing oversight, and ensuring that only high-quality, safe and efficacious biosimilars are available on the market; (ii) ensuring regulatory authorities have adequate capacity to assess and monitor the quality, safety and efficacy of biosimilars throughout their life-cycle; and (iii) monitoring the use of biosimilars in public health systems in collaboration with other stakeholders.</abstract><cop>Switzerland</cop><pub>World Health Organization</pub><pmid>29695884</pmid><doi>10.2471/BLT.17.206284</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0042-9686
ispartof Bulletin of the World Health Organization, 2018-04, Vol.96 (4), p.281-285
issn 0042-9686
1564-0604
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5872015
source International Bibliography of the Social Sciences (IBSS); ABI/INFORM Global (ProQuest); Social Science Premium Collection; Politics Collection; PAIS Index; PubMed Central
subjects Access
Affordability
Biological products
Biological Products - therapeutic use
Biosimilar Pharmaceuticals - therapeutic use
Chronic illnesses
Collaboration
Constraints
Drug and Narcotic Control
Drugs
Effectiveness
Efficacy
Health care
Health Services Accessibility
Humans
Interest groups
Licensure
Life cycles
Manufacturing
Markets
Medical treatment
Oversight
Patients
Pharmacovigilance
Policy & Practice
Process controls
Product safety
Public health
Quality
Quality assessment
Quality standards
Regulatory agencies
Safety
Standardization
Trust
title Regulatory evaluation of biosimilars throughout their product life-cycle
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T02%3A32%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Regulatory%20evaluation%20of%20biosimilars%20throughout%20their%20product%20life-cycle&rft.jtitle=Bulletin%20of%20the%20World%20Health%20Organization&rft.au=Kang,%20Hye-Na&rft.date=2018-04-01&rft.volume=96&rft.issue=4&rft.spage=281&rft.epage=285&rft.pages=281-285&rft.issn=0042-9686&rft.eissn=1564-0604&rft_id=info:doi/10.2471/BLT.17.206284&rft_dat=%3Cproquest_pubme%3E2051199865%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c376t-5e908946daacdac41f1390f62472ad38503bdc7ab67cd0be24ff3934419c83503%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2051199865&rft_id=info:pmid/29695884&rfr_iscdi=true